EVISTA
LOE ApproachingNDAORALTABLET
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
EVISTA by Eli Lilly and Company is agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (serm). Approved for invasive breast cancer, reduction of the risk of recurrence of breast cancer, reduction of risk of noninvasive breast cancer and 1 more indications. First approved in 2007.
Drug data last refreshed 26m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVISTA (raloxifene) is an oral small-molecule selective estrogen receptor modulator (SERM) that acts as an agonist in bone tissue and antagonist in breast and uterine tissues. It is indicated for reduction of risk of invasive breast cancer and recurrence in postmenopausal women. The drug decreases bone resorption, increases bone mineral density, and reduces fracture incidence while lacking estrogen-like effects on uterus and breast.
$0.001BPart D
LOE ApproachingProduct approaching loss of exclusivity with minimal Part D spending ($1M in 2023) and only 2,802 claims, indicating a mature, niche franchise requiring defensive commercial strategy.
Mechanism of Action
agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM). The biological actions of raloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic…
Indications (4)
Worked on EVISTA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.